RxDoctor Payments Data

Kimberly Gray, MD

Family Medicine · Spring, TXNPI 1285077321

Payments from drug & device makers

$2,737in general payments, 2019–2025

Across 137 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$931
  • GSK$378
  • Pfizer$184
  • AbbVie$175
  • Lilly USA, LLC$117
  • Astellas Pharma US Inc$109
  • plus $844 from 20 others

What the payments were for

  • Food & beverage$2,737100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,737 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$42,610
Medicare patients
134
Services billed
388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$110,991
JardianceEmpagliflozin29$31,501
JanuviaSitagliptin Phosphate12$9,635
Atorvastatin Calcium283$3,607
Rosuvastatin Calcium159$2,514
Levothyroxine Sodium199$1,820
Losartan Potassium100$1,776
Nifedipine ErNifedipine42$1,614
Amlodipine Besylate255$1,554
Gabapentin60$1,442
Fluticasone Propionate75$1,288
Albuterol Sulfate HfaAlbuterol Sulfate33$1,219
Metformin Hcl ErMetformin Hcl110$1,182
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide16$1,176
Pantoprazole Sodium102$1,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$931$110,99168 claims
Boehringer IngelheimJardiance$31$31,50129 claims
MerckJanuvia$63$9,63512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Spring

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →